VBI Vaccines (NASDAQ:VBIV) versus Jazz Pharmaceuticals (JAZZ) Critical Contrast

VBI Vaccines (NASDAQ: VBIV) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of current ratings and price targets for VBI Vaccines and Jazz Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VBI Vaccines 0 0 3 0 3.00
Jazz Pharmaceuticals 0 5 17 0 2.77

VBI Vaccines currently has a consensus price target of $10.50, suggesting a potential upside of 146.48%. Jazz Pharmaceuticals has a consensus price target of $183.41, suggesting a potential upside of 29.03%. Given VBI Vaccines’ stronger consensus rating and higher probable upside, equities analysts plainly believe VBI Vaccines is more favorable than Jazz Pharmaceuticals.

Insider & Institutional Ownership

20.9% of VBI Vaccines shares are owned by institutional investors. Comparatively, 90.7% of Jazz Pharmaceuticals shares are owned by institutional investors. 34.1% of VBI Vaccines shares are owned by company insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares VBI Vaccines and Jazz Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VBI Vaccines -4,463.06% -49.17% -37.55%
Jazz Pharmaceuticals 23.58% 22.92% 10.07%

Risk & Volatility

VBI Vaccines has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Earnings & Valuation

This table compares VBI Vaccines and Jazz Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VBI Vaccines $550,000.00 494.24 -$23.20 million ($0.73) -5.84
Jazz Pharmaceuticals $1.49 billion 5.73 $396.83 million $6.07 23.42

Jazz Pharmaceuticals has higher revenue and earnings than VBI Vaccines. VBI Vaccines is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


Jazz Pharmaceuticals beats VBI Vaccines on 9 of the 14 factors compared between the two stocks.

About VBI Vaccines

VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply